COSMIC-313 combines all of the approved drugs against actionable targets in renal cell carcinoma into one triplet regimen. Although this approach has greater clinical efficacy than one of the standard-of-care doublet therapies, toxicities can limit adequate drug administration and, thus, we argue that this regimen should not yet be adopted. We also discuss ongoing investigations of other triplet regimens.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).
Williams, S. D., Loehrer, P. J., Nichols, C. R. & Einhorn, L. N. Chemotherapy of male and female germ cell tumors. Semin. Oncol. 19(Suppl 5), 19–23 (1992). discussion 23–24.
Choueiri, T. K. et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N. Engl. J. Med. 388, 1767–1778 (2023).
Apolo, A. B. et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J. Clin. Oncol. 38, 3672–3684 (2020).
Apolo, A. B. et al. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: results from a discontinued arm of the phase III CheckMate 9ER trial. Eur. J. Cancer 177, 63–71 (2022).
Motzer, R. J. et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 23, 888–898 (2022).
Vano, Y. A. et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 23, 612–624 (2022).
Chen, Y.-W. et al. Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC). J. Clin. Oncol. 41, TPS742 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.E.B. has received institutional research funding from BMS, Eisai, Exelixis, Pfizer and Merck. K.E.B. has acted as a consultant for BMS and Exelixis. B.I.R. has received institutional research funding and/or has acted as a consultant for BMS, Eisai, Exelixis, Pfizer and Merck.
Rights and permissions
About this article
Cite this article
Beckermann, K.E., Rini, B.I. A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma. Nat Rev Clin Oncol 20, 581–582 (2023). https://doi.org/10.1038/s41571-023-00795-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00795-6
